The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Mel'nikov M.V.

Kafedra obshcheĭ khirurgii Sankt-Peterburgskoĭ gosudarstvennoĭ meditsinskoĭ akademii im. I.I. Mechnikova

Kasatkin D.S.

Poliklinika #5, Iaroslavl'

Volkov A.I.

Gosudarstvennyĭ nauchnyĭ tsentr sotsial'noĭ i sudebnoĭ psikhiatrii im. V.P. Serbskogo

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

The pegylated form of interferon beta in the treatment of multiple sclerosis

Authors:

Mel'nikov M.V., Kasatkin D.S., Volkov A.I., Boĭko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(8): 136‑141

DOI: 10.17116/jnevro2019119081136

Read: 3758 times

Download PDF (RU)
Contact the author
Table of contents

THE PEGYLATED FORM OF INTERFERON BETA IN THE TREATMENT OF MULTIPLE SCLEROSIS
THE PEGYLATED FORM OF INTERFERON BETA IN THE TREATMENT OF MULTIPLE SCLEROSIS

To cite this article:

Mel'nikov MV, Kasatkin DS, Volkov AI, Boĭko AN. The pegylated form of interferon beta in the treatment of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(8):136‑141. (In Russ.)
https://doi.org/10.17116/jnevro2019119081136

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Mole­cular mechanisms of acute disseminated ence­phalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Resu­lts of a 5-year project for the early diagnosis of multiple scle­rosis in first-line blood rela­tives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Features of the clinical course of multiple scle­rosis as a factor in persistent disa­bility. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44
Quantitative analysis of cere­brospinal fluid flow in multiple scle­rosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):45-50
Expe­rience of using ribo­ciclib in the therapy of meta­static breast cancer in a regional onco­logical dispensary. P.A. Herzen Journal of Onco­logy. 2025;(3):89-93
Abstract:

Interferons-beta (IFN-β) along with glatiramer acetate is one of the most commonly used disease modifying treatment (DMT) of multiple sclerosis (MS) associated with effectiveness and acceptable safety profile. At the same time, therapy with IFN-β has a number of limitations associated with a high frequency of injections and production of neutralizing antibodies. The development of the pegylated form of IFN-β (PEG-IFN-β) is aimed at resolving these issues. This article reviewed the mechanism of action, efficacy, safety and tolerability of PEG-IFN-β in the treatment of MS.

Keywords:

multiple sclerosis
pegylated interferon-beta
efficacy
safety

Authors:

Mel'nikov M.V.

Kafedra obshcheĭ khirurgii Sankt-Peterburgskoĭ gosudarstvennoĭ meditsinskoĭ akademii im. I.I. Mechnikova

Kasatkin D.S.

Poliklinika #5, Iaroslavl'

Volkov A.I.

Gosudarstvennyĭ nauchnyĭ tsentr sotsial'noĭ i sudebnoĭ psikhiatrii im. V.P. Serbskogo

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Close metadata

References:

  1. Boyko AN, Davydovskaya MV, Demina TL, Lashch NYu, Ovcharov VV, Popova NF, Sidorenko TV, Sinbukhova NI, Trubachenko AV, Khachanova NV, Gusev EI. The experience of long-term use of betaferon and copaxone in the daily practice of neurologists is the results of 5 years of treatment of patients with multiple sclerosis in the Moscow city center of multiple sclerosis. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2007;107(4):84-94. (In Russ.)
  2. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30(2):89-100. https://doi.org/10.2165/11533330-000000000-00000
  3. Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, Donnellan N, Comabella M, Montalban X, Kieseier B, Soelberg Sørensen P, Hartung HP, Derfuss T, Lawton A, Sikkema D, Pallardy M, Hemmer B, Deisenhammer F, Broët P, Dönnes P, Davidson J, Fogdell-Hahn A; ABIRISK Consortium. Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. PLoS One. 2017;12(2):e0170395. https://doi.org/10.1371/journal.pone.0170395
  4. Tolley K, Hutchinson M, You X, Wang P, Sperling B, Taneja A, Siddiqui MK, Kinter E. A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other injectable therapies for the treatment of relapsing-remitting multiple sclerosis. PLoS One. 2015;10(6):e0127960. https://doi.org/10.1371/journal.pone.0127960
  5. Jain A, Jain SK. PEGylation: an approach for drug delivery. A review. Crit Rev Ther Drug Carrier Syst. 2008;25(5):403-447.
  6. Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv. 2009;6(1):1-16. https://doi.org/10.1517/17425240802650568
  7. Kang JS, Deluca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs. 2009;14(2):363-380. https://doi.org/10.1517/14728210902907847
  8. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci. 2008;97(10):4167-4183. https://doi.org/10.1002/jps.21278
  9. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2(3):214-221.
  10. Gilli F, De La Torre AL, Royce DB, Pachner AR. Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta. Int Immunopharmacol. 2018;62:1-6. https://doi.org/10.1016/j.intimp.2018.06.030
  11. Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, Smith D. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos. 2007;35(1):9-16.
  12. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000;68(5):556-567.
  13. Yen JH, Kong W, Ganea D. IFN-beta inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9. J Immunol. 2010;184(7):3478-3486. https://doi.org/10.4049/jimmunol.0902542
  14. Tao Y, Zhang X, Zivadinov R, Dwyer MG, Kennedy C, Bergsland N, Ramasamy D, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B, Markovic-Plese S. Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e176. https://doi.org/10.1212/NXI.0000000000000176
  15. Balasa R, Maier S, Voidazan S, Hutanu A, Bajko Z, Motataianu A, Tilea B, Tiu C. Assessment of Interleukin-17A, Interleukin-10 and transforming growth factor-beta1 serum titers in relapsing remitting multiple sclerosis patients treated with avonex, possible biomarkers for treatment response. CNS Neurol Disord Drug Targets. 2017;16(1):93-101. https://doi.org/10.2174/1871527315666160615110739
  16. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13(7):657-665. https://doi.org/10.1016/S1474-4422(14)70068-7
  17. Newsome SD, Scott TF, Arnold DL, Nelles G, Hung S, Cui Y, Shang S, Naylor ML, Kremenchutzky M. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. Ther Adv Neurol Disord. 2018;11:1756286418791143. https://doi.org/10.1177/1756286418791143
  18. Naismith RT, Hendin B, Wray S, Huang D, Gaudenzi F, Dong Q, Sperling B, Mann M, Werneburg B. Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results. Mult Scler J Exp Transl Clin. 2019;5(1):2055217318822148. https://doi.org/10.1177/2055217318822148
  19. Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis. Mult Scler Relat Disord. 2016;9:23-30. https://doi.org/10.1016/j.msard.2016.06.001
  20. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM The global adherence project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18:69-77. https://doi.org/10.1111/j.1468-1331.2010.03110.x
  21. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497. https://doi.org/10.1056/NEJMra050100
  22. Tan H. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28:51-61. https://doi.org/10.1007/s12325-010-0093-7
  23. Agashila N, Wu N, Abouzaid S, Wu Y, Kim E, Boulanger L, Brandes DW. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol. 2013;13:138. https://doi.org/10.1186/1471-2377-13-138
  24. Portaccio E, Amato MP. Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23:453-462. https://doi.org/10.2165/00023210-200923060-00001
  25. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008;10(9):225.
  26. Howley A, Kremenchutzky M. Pegylated interferons: a nurses’ review of a novel multiple sclerosis therapy. J Neurosci Nurs. 2014;46(2):88-96. https://doi.org/10.1097/JNN.0000000000000039
  27. Spirin NN, Kasatkin DS, Stepanov IO, Shipova EG, Baranova NS. Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2012;112(8):27-33. (In Russ.)
  28. Kasatkin DS, Spirin NN, Boĭko AN, Vlasov YaV. Unified assessment of adverse events of multiple sclerosis disease modifying drugs. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2014;114:2/2:78-82. (In Russ.)
  29. Kasatkin DS, Spirin N.N. Influenza-like syndrome during interferon-beta therapy. Bulletin of Novosibirsk State University. Series: Biology, Clinical Medicine. 2015;13(1):30-37. (In Russ.)
  30. Naismith RT, Hendin B, Wray S, Huang D, Gaudenzi F, Dong Q, Sperling B, Mann M, Werneburg B. Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results. Mult Scler J Exp Transl Clin. 2019;5(1):2055217318822148. https://doi.org/10.1177/2055217318822148
  31. Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology. 1999;53(8):1622-1627.
  32. Balak DM, Hengstman GJ, Çakmak A, Thio HB. Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review. Mult Scler. 2012;18:1705-1717.
  33. Hu X, Shang S, Nestorov I, Hasan J, Seddighzadeh A, Dawson K, Sperling B, Werneburg B. COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects. Br J Clin Pharmacol. 2016;82:380-388.
  34. Hendin B, Huang D, Wray S, Naismith RT, Rosenblatt S, Zambrano J, Werneburg B. Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study. Neurodegener Dis Manag. 2017;7:39-47.
  35. Halper J, Centonze D, Newsome SD, Huang D, Robertson C, You X, Sabatella G, Evilevitch V, Leahy L. Management strategies for flu-like symptoms and injection-site reactions associated with peginterferon Beta-1a: Obtaining recommendations using the Delphi technique. Int J MS Care. 2016;18:211-218.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.